News

Kaléo Announces Chief Development Officer

Kaléo, a fully integrated pharmaceutical company dedicated to inventing, manufacturing, and commercializing life-transforming products, today announced the appointment of Theresa Matkovits, Ph.D., as its new Chief Development Officer.

Dr. Matkovits brings a wealth of experience as a transformational C-suite business leader with a strong track record of driving global drug development and commercialization efforts. With a deep background in working across multiple therapeutic areas and successfully leading organizations through regulatory approvals, Dr. Matkovits will play a critical role in Kaléo’s continued expansion and development of the company’s innovative Aerio™ Auto-Injector Platform. Her appointment comes at an exciting time for Kaléo, which recently secured key contracts with the U.S. Department of Defense and the Department of Health and Human Services, further strengthening the company’s role in providing medical countermeasures.

“Theresa’s extensive experience in leading global drug development and commercialization will be a key asset as we continue to leverage our innovative product portfolio to expand our medical countermeasures business,” said Michael Wells, Chairman and Chief Executive Officer of Kaléo. “Her proven ability to navigate regulatory landscapes and drive operational excellence makes her an outstanding addition to our executive team.”

Prior to joining Kaléo, Dr. Matkovits served as Chief Development Officer for Matinas Biopharma, where she led the company’s clinical-stage asset and secured strategic partnerships with key organizations such as the NIH and the Cystic Fibrosis Foundation. Throughout her extensive career, she has held leadership positions at NPS Pharmaceuticals, The Medicines Company, and Novartis, making significant contributions to drug development, regulatory advocacy, and commercialization efforts.

Read more here.

Recent News

11/08/2024

Catalyzing Crucial Cross-Border Collaborations and Innovation to Address Unmet Needs in Rare Diseases

The World Health Organization (WHO) defines a rare disease (RD), or orphan disease, as affecting fewer than 65 per 100,000 people. Although individual RDs are uncommon, collectively, over 10,000 rare diseases impact about 400 million people globally—roughly 5% of the world’s population. Almost 95% of these diseases remain without a single approved treatment. Orphan drugs

11/05/2024

Adial Pharmaceuticals Appoints Vinay Shah as Chief Financial Officer

Adial Pharmaceuticals, Inc. a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today announced the appointment of Vinay Shah as the Company’s Chief Financial Officer, effective November 16, 2024. Vinay Shah is an accomplished Chief Financial Officer with over 25 years of experience in the pharmaceutical,

10/29/2024

Kaléo Announces Chief Development Officer

Kaléo, a fully integrated pharmaceutical company dedicated to inventing, manufacturing, and commercializing life-transforming products, today announced the appointment of Theresa Matkovits, Ph.D., as its new Chief Development Officer. Dr. Matkovits brings a wealth of experience as a transformational C-suite business leader with a strong track record of driving global drug development and commercialization efforts. With